ARGENX SE - ADR (ARGX)
US04016X1019 - ADR
argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024
May 2, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people...
argenx Becomes Oversold (ARGX)
argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease
ADHERE data show VYVGART® Hytrulo has potential to be first advancement for CIDP patients in 30 years Real-world data demonstrate gMG patients able to...
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
argenx Advances Clinical Development of Efgartigimod in Primary Sjogren’s Disease
RHO study supports proof-of-concept in primary Sjogren’s disease Decision informed by favorable safety profile and consistency across efficacy...
argenx Announces Annual General Meeting of Shareholders on May 7, 2024
argenx Announces Annual General Meeting of Shareholders on May 7, 2024
March 26, 2024 Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of...
argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia
VYVGART® now approved in Japan for both generalized myasthenia gravis and primary immune thrombocytopenia (ITP) Regulatory decision in Japan represents...
Argenx, Immunovant Soar — As Tourmaline Plummets — On A Rival's Lackluster Test Results
Investors saw Chugai's experimental drug as a potential rival to Argenx's approved medicine, Vyvgart.
argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting
ADHERE data presentation will highlight first potential innovation for CIDP patients in 30 years Abstracts reflect real-world value and consistent...
argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update
$374 million in fourth quarter and $1.2 billion in full year global net product sales sBLA for VYVGART® Hytrulo for CIDP accepted for priority review by...
argenx to Present at Upcoming Investor Conferences
argenx to Present at Upcoming Investor Conferences
February 26, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of...
argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024
February 22, 2024Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of...
3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition
Now could be the time to start looking into these biotech stocks as there are imminent approvals on their clinical trials.
argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy
Prescription Drug User Fee Act (PDUFA) target action date is June 21, 2024 If approved, VYVGART® Hytrulo will be the first neonatal Fc receptor (FcRn)...
Regeneron’s Eylea HD, argenx’s Vyvdura approved in Japan
In Japan, Bayer (BAYRY) and argenx (ARGX) have received regulatory approvals for eye therapy high-dose Eylea and autoimmune therapy, Vyvdura, respectively.
argenx Announces Approval of VYVDURA® (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis
Availability of VYVGART® and self-administered VYVDURA demonstrates continued commitment to providing more choice and flexibility for gMG patients in...
5 Biotech Stocks That Could Be Big Winners in 2024 and Beyond
These five biotech companies could have a lot of room to run.